Sequential influenza b viral load and susceptibility in children treated with oseltamivir and zanamivir

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages

  Sato, Masatoki ^a,b   Honzumi, Ken ^a   Sato, Toshiko ^a   Hashimoto, Koichi ^a   Watanabe, Masahiro ^b   Miyazaki, Kyohei ^a   Kawasaki, Yukihiko ^a   Hosoya, Mitsuaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Department of Pediatrics   (Japan)

Author keywords

antiviral therapy; influenza; neuraminidase inhibitor; oseltamivir; zanamivir

Indexed keywords

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IC 50; INFECTION SENSITIVITY; INFLUENZA B; INFLUENZA VIRUS B; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS LOAD; DRUG EFFECTS; INFANT; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; NOSE CAVITY; PRESCHOOL CHILD; VIROLOGY;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; NASAL CAVITY; OSELTAMIVIR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD; ZANAMIVIR;

EID: 84902548992     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000266     Document Type: Article

References (34)

1. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342:225-231.
2. Shuler CM, Iwamoto M, Bridges CB, et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics. 2007;119:e587-e595.
3. Eisenberg KW, Szilagyi PG, Fairbrother G, et al.; New Vaccine Surveillance Network. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics. 2008;122:911-919.
4. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290:1608-1616.
5. Katayose M, Hosoya M, Haneda T, et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine. 2011;29:1844-1849.
6. Hayden FG, Cote KM, Douglas RG Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980;17:865-870.
7. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119-130.
8. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-1024.
9. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-1850.
10. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352: 1877-1881.
11. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-880.
12. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133.
13. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-417.
14. Puhakka T, Lehti H, Vainionpää R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis. 2003;35:52-58.
15. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24:931-932.
16. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395-2402.
17. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis. 2013;56:1197-1205.
18. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-765.
19. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011;52:432-437.
20. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43:1555-1561.
21. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47: 2264-2272.
22. Tashiro M, McKimm-Breschkin JL, Saito T, et al.; Neuraminidase Inhibitor Susceptibility Network. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther. 2009;14:751-761.
23. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-1442.
24. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
25. Divanovic S, Lai AC. Cytokine induction in human cord blood lymphocytes after pulsing with UV-inactivated influenza viruses. Immunol Lett. 2004;94:201-207.
26. Sato M, Hosoya M, Wright PF. Differences in serum cytokine levels between influenza virus A and B infections in children. Cytokine. 2009;47:65-68.
27. Ward CL, Dempsey MH, Ring CJ, et al. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol. 2004;29:179-188.
28. A US Food and Drug Administration. MedWatchthe FDA safety information and adverse event reporting program. Relenza (zanamivir) inhalation powder. 2009. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm186081.htm. Accessed December 12, 2013.
29. Steel HM, Peppercorn AF. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis. 2010;51:121.
30. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis. 2010;50:620.
31. Peng AW, Hussey EK, Rosolowski B, et al. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. Curr Ther Res. 2000;61:36-46.
32. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36 (suppl 1):1-11.
33. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500.
34. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-3292.